This year's award marks 30 years since clinicians first used ECP to successfully treat chronic graft versus host disease (cGvHD).1 In recognition of this important milestone, this year's $75,000 grant was dedicated to advancing research...
Read More
In recognition of 30 years of Extracorporeal Photopheresis Use for Chronic Graft vs. Host Disease (cGvHD), this year's grant is to be dedicated to research in cGvHD Investigators of ECP...
Read More
Analysis of published studies of extracorporeal photopheresis (ECP) treatment for steroid-refractory chronic graft-versus-host disease (SR-cGvHD) assessed that THERAKOS ECP can improve short- and long-term patient outcomes1 THIS INFORMATION IS INTENDED...
Read More
Results from the largest European and first multicenter, retrospective, observational chart review study investigating the real-world use of ECP in heart transplant patients reinforce its use as a treatment for...
Read More
CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD DUBLIN – March 9, 2023 – Mallinckrodt plc, (NYSE American: MNK)(“Mallinckrodt” or...
Read More
Winning project hopes to unlock invaluable insights on how ECP could improve quality of life and clinical outcomes in chronic lung allograft dysfunction DUBLIN, Nov.16, 2022 -- Mallinckrodt plc (NYSE American:...
Read More
Retrospective medical chart review study assessed real world treatment patterns and outcomes DUBLIN, Dec. 13, 2021 /PRNewswire/ -- Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational...
Read More
In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison DUBLIN, Ireland and LAKEWOOD, Colo. USA...
Read More
Analysis from the largest known, ongoing, retrospective, explorative, single-arm, pan-European multicenter study of ECP in heart transplant patients suggests potential for ECP in the treatment of acute cellular rejection, antibody...
Read More
Rich diversity of cutting-edge ECP science represented in Mallinckrodt’s 2021 research award Dublin, Ireland, March 19, 2021 – A project that will analyze the immunomodulatory effects of extracorporeal photopheresis therapy...
Read More